Walden, the leader in pharmaceutical logistics in Europe acquires the Belgian pharmaceutical transport company Ivemar
The group integrates the Belgian company to support the development of its subsidiary Transpharma International, which specialises in first-mile pharmaceutical transport and global freight forwarding.
«The acquisition of Ivemar provides Transpharma International with transport assets, a strong team well practised in GDP and licensed premises located in a key European trade corridor for transport and logistics.” Says David Evans, CEO of Transpharma International.
The addition of Ivemar fleet which grow Transpharma International’s GDP fleet in Europe to over 250 vehicles offering pan-European temperature-controlled transport for shipments of all sizes (1 pallet up to full truck load). More importantly this also sees the business develop its capability for in-transit storage and cross-docking at licensed warehouse locations close to Brussels, and the addition of licensed and temperature-controlled storage at Brussels airport which is a key development in Transpharma International’s strategy to further grow its offering in pharma compliant air freight solutions.
The addition of storage capacity directly at the aircraft exit now enables Transpharma International to strengthen its service offering. Until now, Transpharma International has focused solely on the first-mile transport phase, from APIs to finished products, and can now offer temperature-controlled GDP storage solutions for goods in transit, as well as storage of supply flows (raw materials, APIs…) to manufacturers from and to the rest of the world.
“As founder and CEO of Ivemar, I am delighted to see the company joining the Walden Group and giving it the chance to grow in a sustainable way. Our expertise and infrastructure are the perfect complement to Transpharma International’s network and capabilities, it’s a great opportunity to bring additional expertise to the group” says Yves SMETS, CEO of Ivemar.
About Walden
Founded in 1951 in France, the Walden Group is a family-owned company whose ambition is to become a global player in supply chain and logistics. Its activities are grouped around two poles of expertise: on logistics and transport of healthcare products (with Movianto for logistics, Eurotranspharma for temperature-controlled last mile transport and Transpharma International for first mile transport) and on express transport (with Ciblex and Relais Colis). To support these activities, the subsidiary Pharma Pilot develops IT and digital solutions tailored to the specific needs of the group’s customers. The Walden Group is present in 15 countries (France, Spain, Germany, the Netherlands, Belgium, Denmark, UK, Ireland, Switzerland, Morocco, Poland, the Czech Republic, Slovakia, India and Romania), employs more than 6 000 people on 180 sites and nearly 800,000 m² of warehouses. In 2022 the group had a turnover of €2.6 billion.
About Transpharma International
Transpharma International is part of the Walden group and focuses on delivering GDP compliant freight forwarding solutions for the healthcare and life sciences industry. Transpharma International transports healthcare products worldwide with 200 owned vehicles and a strategic network of 3000 vehicles in Europe. They offer first mile transport services covering all temperature ranges for manufacturers and distributors through its multiple locations in Europe. In addition, Transpharma International has developed a range of valued added services such as customs management and consultancy services.
English (UK) 
Français 
About The Author
Laure Murat